Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

By sjmartinez • August 15, 2024

Rastogi A, Collins A, Kelepouris E, Kotzker W, Middleton JP, Rajpal M, Roy-Chaudhury P, Chertow GM. Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241259905. doi: 10.1177/21501319241259905. PMID: 39143759.

Tags: Chronic kidney disease, consensus, KDIGO, Nephrology, Publications, SGLT2 inhibitor, treatment algorithm

Declining Serum Albumin With Stable Body Mass Index: A Mortality Indicator in Predialysis Chronic Kidney Disease

Sarav M, Shrestha P, Naseer A, Thomas F, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Declining Serum Albumin With Stable Body Mass Index: A Mortality Indicator[...]

Trimethylamine- N-Oxide Affects Cell Type-Specific Pathways and Networks in Mouse Aorta to Promote Atherosclerotic Plaque Vulnerability

Cheng J, Cheng M, Sinha S, Cely I, Gladkikh S, Han MT, Zhang G, Zhou Z, Chugh R, Ahn IS, Diamante G, Wang YC, Wang[...]

Efficacy of Acthar gel and Tacrolimus in DNA-JB9 Positive Fibrillary Glomerulopathy

Tumlin JA, Podoll A, Kopyt N, Rovin B, Lafayette R, Bomback A, Glassock R, Whitson J, Press A, Appel GB. Efficacy of Acthar gel and[...]